RESUMO
Purpose: Although risk factors related to chemotherapy-induced nausea and vomiting (CINV) have been identified in previous studies, only a few studies have evaluated the risk factors associated with contemporary antiemetic prophylaxis, including olanzapine/aprepitant- or NEPA-containing regimens. This study aimed to identify the risk factors associated with CINV development in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy. Methods: Data from 304 patients enrolled in 3 previously reported prospective antiemetic studies were included. Multivariate logistic regression models were used to predict risk factors associated with CINV occurrence. Additionally, the likelihood of treatment failure in relation to the number of risk factors in individual patients was evaluated. Results: Multivariate analysis of the entire study group revealed that obesity status (defined as body mass index/= 25.0 kg/m2) and the use of olanzapine/aprepitant- or NEPA-containing anti-emetic regimens were associated with a high likelihood, while a history of motion sickness was associated with a lower likelihood, complete response (CR), and "no nausea" in the overall phase. A history of vomiting during pregnancy was also associated with a lower likelihood of an overall CR. Patients with an increasing number of risk factors had a higher likelihood of treatment failure and shorter time to first vomiting. Those who did not achieve CR and "no nausea" in the first cycle were less likely to achieve these parameters in the subsequent cycle of chemotherapy. Conclusion: The present study confirmed previously reported risk factors for CINV in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide. Further optimization of CINV control is required for patients with identifiable risk factors; olanzapine/aprepitant- or NEPA- containing prophylaxis are the preferred contemporary anti-emetics regimens for Chinese breast cancer patients undergoing doxorubicin and cyclophosphamide chemotherapy.
RESUMO
Getting vaccinated against SARS-CoV-2 lowers the risk of severe infections. In Hong Kong, two vaccine types are offered: CoronaVac by Sinovac Biotech (Sinovac), and Comirnaty by BioNTech-Fosun Pharma (BioNTech). However, a low vaccine uptake rate is observed. This study primarily aimed to determine the population of medical students who underwent COVID-19 vaccination, and to identify factors associated with their decision on timing and vaccine type. Current medical students from The University of Hong Kong (HKU) were invited to participate in this cross-sectional survey study from 16 September to 31 December 2021. The main outcome measures were the vaccine uptake rate, primary reasons for vaccine-seeking behavior, vaccine hesitancy and vaccine preference, as well as information sources. All questions were of a multiple-choice format, with a free response option for questions pertaining to reason exploration. Overall, 214 medical students participated in the study, with all questionnaires analyzed. Amongst the 98.1% that completed 2 doses, 93.4% selected BioNTech and 6.6% selected Sinovac. Significant associations were observed between year groups and vaccine timing (p = 0.00989). The primary reason to seek vaccination was immunity against COVID-19 (53.5%), while the fear of potential side effects (61.6%) accounted for vaccine hesitancy. The BioNTech vaccine was favored for its higher efficacy against COVID-19 (87.4%). Information sources were mainly from HKU professors (64.6%) and social media (59.9%). The study found a high vaccine uptake rate amongst medical students, contrary to the situation observed in the Hong Kong general population at the time of the study.
This is the first paper evaluating the attitudes and behaviours of Hong Kong medical students towards the COVID-19 vaccine.High COVID-19 vaccine uptake observed amongst HKU medical students, with a predilection towards Comirnaty by BioNTech-Fosun Pharma for the first and second dose.Clinical medical students are more likely to get their COVID-19 vaccine earlier than preclinical medical students.Immunity against COVID-19 was the most compelling reason for students to get vaccinated, whilst fears over side effects was the main reason for vaccine hesitancy.
